Q-omics provides the consensus-scored PCDHGA1 profile across patient tissues and cancer cell-line models. PCDHGA1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, PCDHGA1 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, PCDHGA1 RNA expression shows 15,285 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BLCA, HNSC, and TGCT as cancer lineages where PCDHGA1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PCDHGA1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PCDHGA1 survival associations across molecular data types. PCDHGA1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PCDHGA1 RNA expression–survival associations across cancer types. High PCDHGA1 expression shows unfavorable associations in BLCA, BRCA, LUAD, CESC and UCS, but favorable associations in ACC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for PCDHGA1 RNA expression.
This table summarizes PCDHGA1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for PCDHGA1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PCDHGA1 shows higher tumor expression in HNSC, KIRC, COAD, LIHC, LUAD and KIRP. The HNSC box plot shows higher PCDHGA1 RNA expression in tumor versus normal tissue (log2 FC = +0.664, t-test p < 0.001).
This table shows molecular features associated with PCDHGA1 in patient tissues and cancer cell lines. In patient samples, PCDHGA1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, PCDHGA1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
